Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 142   

Articles published

GSK 1,546.30 -6.70 (-0.43%)
price chart
GlaxoSmithKline plc 14.8% Potential Upside Indicated by Jefferies International
GlaxoSmithKline plc with EPIC/TICKER LON:GSK has had its stock rating noted as 'Reiterates' with the recommendation being set at 'BUY' today by analysts at Jefferies International.
GlaxoSmithKline PLC (GSK) Downgraded by Zacks Investment Research  Sports Perspectives
The GlaxoSmithKline plc (GSK) Stock Rating Reaffirmed by Shore Capital  DailyQuint
GlaxoSmithKline plc 21.7% Potential Upside Indicated by Liberum Capital
GlaxoSmithKline plc using EPIC/TICKER code LON:GSK had its stock rating noted as 'Reiterates' with the recommendation being set at 'BUY' today by analysts at Liberum Capital.
GlaxoSmithKline plc (GSK) Receives Average Rating of "Hold" from ...  BBNS
The GlaxoSmithKline plc (GSK) Rating Reiterated by BNP Paribas  DailyQuint
Why I'm bullish on GlaxoSmithKline plc for 2017
I believe GlaxoSmithKline (LSE: GSK) is one of the market's most undervalued and under-appreciated stocks. Over the past year, the company has gone from a business struggling to grow, to projected earnings per share growth of 30% this year and 10% for ...
Notable Stock Analysts Ratings: GlaxoSmithKline plc (NYSE:GSK)
GlaxoSmithKline plc (NYSE:GSK) will report its next earnings on Feb 1 - Feb 6 (Est.). The company reported the earnings of $0.85/Share in the last quarter where the estimated EPS by analysts was $0.74/share.
GlaxoSmithKline plc 10% Potential Upside Indicated by Jefferies International
GlaxoSmithKline plc using EPIC/TICKER code LON:GSK has had its stock rating noted as 'Reiterates' with the recommendation being set at 'BUY' this morning by analysts at Jefferies International.
Simon Dingemans Buys 8 Shares of GlaxoSmithKline plc (GSK) Stock  Sports Perspectives
J P Morgan Chase & Co Reiterates "Neutral" Rating for ...  BBNS
GlaxoSmithKline plc's (GSK) "Underperform" Rating Reaffirmed at BNP Paribas
GlaxoSmithKline plc logo BNP Paribas reiterated their underperform rating on shares of GlaxoSmithKline plc (LON:GSK) in a research note issued to investors on Sunday morning.
Revenue Estimates Analysis: GlaxoSmithKline plc (NYSE:GSK)  News Oracle
GlaxoSmithKline plc (GSK) Rating Reiterated by BNP Paribas  The Cerbat Gem
Does this pharma's 56% sales growth make it a better buy than GlaxoSmithKline plc?
Reporting a 56% rise in sales for the first half of a financial year is a stunning performance by any investor's standards. Of course, the pharma stock in question was aided by weak sterling, which added 22% of those gains.
GSK 'looks like a technical buy' for 2017
UK pharma giant GlaxoSmithKline plc (LON:GSK) is a 'technical buy' for the coming year after a volatile year for drugs stocks has seen the share price fall, says Zak Mir.
Zak Mir tips three big names to do well in 2017  MENAFN.COM
Does EKF Diagnostics Holding plc have more upside than GlaxoSmithKline plc ...
Point of care business EKF Diagnostics (LSE: EKF) has risen by over 5% today. This sharp hike in its share price is due to a positive update which shows that it has beaten expectations for the 2016 financial year.
what are Analysts report about: GlaxoSmithKline plc (NYSE:GSK)
GlaxoSmithKline plc (NYSE:GSK) will report its next earnings on Feb 1 - Feb 6 (Est.). The company reported the earnings of $0.85/Share in the last quarter where the estimated EPS by analysts was $0.74/share.
GlaxoSmithKline plc (GSK) Insider Moncef Slaoui Acquires 58 Shares  Sports Perspectives
Large Buying Action and Inflow of Money Witnessed in GlaxoSmithKline PLC  Highland Mirror